M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding

Retrovirology

Kevin K Ariën¹  James M Binley³  Guido Vanham⁴  Loïc Martin²  Ema T Crooks³  Tommy Tong³  Katrijn Grupping¹  Philippe Selhorst¹ 

[1] Department of Biomedical Sciences, Unit of Virology, Institute of Tropical Medicine, Antwerp, B-2000, Belgium;Commissariat à l'énergie atomique et aux énergies alternatives, iBiTecS, SIMOPRO, Gif sur Yvette, F-91191, France;Torrey Pines Institute for Molecular Studies, San Diego, CA 92121, USA;Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, B-2000, Belgium

关键词: Inhibition;    Shedding;    gp120;    CD4 binding site;    Entry;    HIV;   

Others  :  1209168
DOI  :  10.1186/1742-4690-10-12

 received in 2012-06-19, accepted in 2013-01-08,  发布年份 2013

【 摘 要 】

Background

HIV-1 infected cells can establish new infections by crossing the vaginal epithelia and subsequently producing virus in a milieu that avoids the high microbicide concentrations of the vaginal lumen.

Findings

To address this problem, here, we report that pretreatment of HIV-infected peripheral blood mononuclear cells (PBMCs) with a 27 amino acid CD4-mimetic, M48U1, causes dramatic and prolonged reduction of infectious virus output, due to its induction of gp120 shedding.

Conclusions

M48U1 may, therefore, be valuable for prophylaxis of mucosal HIV-1 transmission.

【 授权许可】

   
2013 Selhorst et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Butler DM, Delport W, Kosakovsky Pond SL, Lakdawala MK, Cheng PM, Little SJ, Richman DD, Smith DM: The Origins of Sexually Transmitted HIV Among Men Who Have Sex with Men. Sci Transl Med 2010, 2:18re11.
• [2]Anderson DJ, Politch JA, Nadolski AM, Blaskewicz CD, Pudney J, Mayer KH: Targeting Trojan Horse leukocytes for HIV prevention. AIDS 2010, 24:163-187.
• [3]Ariën KK, Jespers V, Vanham G: HIV sexual transmission and microbicides. Rev Med Virol 2011, 21:110-133.
• [4]Ibata B, Parr EL, King NJ, Parr MB: Migration of foreign lymphocytes from the mouse vagina into the cervicovaginal mucosa and to the iliac lymph nodes. Biol Reprod 1997, 56:537-543.
• [5]Di Fabio S, Giannini G, Lapenta C, Spada M, Binelli A, Germinario E, Sestili P, Belardelli F, Proietti E, Vella S: Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. AIDS 2001, 15:2231-2238.
• [6]Khanna KV, Whaley KJ, Zeitlin L, Moench TR, Mehrazar K, Cone RA, Liao Z, Hildreth JE, Hoen TE, Shultz L, Markham RB: Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest 2002, 109:205-220.
• [7]Sallé B, Brochard P, Bourry O, Mannioui A, Andrieu T, Prevot S, Dejucq-Rainsford N, Dereuddre-Bosquet N, Le Grand R: Infection of Macaques after Vaginal Exposure to Cell-Associated Simian Immunodeficiency Virus. J Infect Dis 2010, 202:337-344.
• [8]Weiler AM, Li Q, Duan L, Kaizu M, Weisgrau KL, Friedrich TC, Reynolds MR, Haase AT, Rakasz EG: Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239. J Virol 2008, 82:4154-4158.
• [9]Zacharopoulos VR, Perotti ME, Phillips DM: A role for cell migration in the sexual transmission of HIV-1? Curr Biol 1997, 7:534-537.
• [10]Martin N, Welsch S, Jolly C, Briggs JAG, Vaux D, Sattentau QJ: Virological Synapse-Mediated Spread of Human Immunodeficiency Virus Type 1 between T Cells Is Sensitive to Entry Inhibition. J Virol 2010, 84:3516-3527.
• [11]Massanella M, Puigdomenech I, Cabrera C, Fernandez-Figueras MT, Aucher A, Gaibelet G, Hudrisier D, García E, Bofill M, Clotet B, Blanco J: Antigp41 antibodies fail to block early events of virological synapses but inhibit HIV spread between T cells. AIDS 2009, 23:183-188.
• [12]Selhorst P, Grupping K, Bourlet T, Delézay O, Ariën KK, Vanham G: In Vitro Activities of Candidate Microbicides against Cell-Associated HIV. Antimicrob Agents Chemother 2012, 56:805-815.
• [13]Nuttall JP, Thake DC, Lewis MG, Ferkany JW, Romano JW, Mitchnick MA: Concentrations of Dapivirine in the Rhesus Macaque and Rabbit following Once Daily Intravaginal Administration of a Gel Formulation of [14C]Dapivirine for 7 Days. Antimicrob Agents Chemother 2008, 52:909-914.
• [14]Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA: Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997, 71:3023-3030.
• [15]Martin L, Stricher F, Misse D, Sironi F, Pugniere M, Barthe P, Prado-Gotor R, Freulon I, Magne X, Roumestand C, Ménez A, Lusso P, Veas F, Vita C: Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotech 2003, 21:71-76.
• [16]Van Herrewege Y, Morellato L, Descours A, Aerts L, Michiels J, Heyndrickx L, Martin L, Vanham G: CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. J Antimicrob Chemother 2008, 61:818-826.
• [17]Dereuddre-Bosquet N, Morellato-Castillo L, Brouwers J, Augustijns P, Bouchemal K, Ponchel G, Ramos OH, Herrera C, Stefanidou M, Shattock R, Heyndrickx L, Vanham G, Kessler P, Le Grand R, Martin L: MiniCD4 Microbicide Prevents HIV Infection of Human Mucosal Explants and Vaginal Transmission of SHIV(162P3) in Cynomolgus Macaques. PLoS Pathog 2012, 8(12):e1003071.
• [18]Grupping K, Selhorst P, Michiels J, Vereecken K, Heyndrickx L, Kessler P, Vanham G, Martin L, Ariën KK: MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency. Retrovirology 2012, 9:36. BioMed Central Full Text
• [19]Tong T, Crooks ET, Osawa K, Binley JM: HIV-1 Virus-Like Particles Bearing Pure Env Trimers Expose Neutralizing Epitopes but Occlude Non-Neutralizing Epitopes. J Virol 2012, 86:3574-3587.
• [20]Motakis D, Parniak MA: A Tight-Binding Mode of Inhibition Is Essential for Anti-Human Immunodeficiency Virus Type 1 Virucidal Activity of Nonnucleoside Reverse Transcriptase Inhibitors. Antimicrob Agents Chemother 2002, 46:1851-1856.
• [21]Hart TK, Kirsh R, Ellens H, Sweet RW, Lambert DM, Petteway SR: Jr, Leary J, Bugelski PJ: Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc Natl Acad Sci USA 1991, 88:2189-2193.
• [22]Moore JP, McKeating JA, Weiss RA, Sattentau QJ: Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 1990, 250:1139-1142.
• [23]Ruprecht CR, Krarup A, Reynell L, Mann AM, Brandenberg OF, Berlinger L, Abela IA, Regoes RR, Günthard HF, Rusert P, Trkola A: MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J Exp Med 2011, 208:439-454.
• [24]Haase AT: Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464:217-223.
• [25]Kouokam JC, Huskens D, Schols D, Johannemann A, Riedell SK, Walter W, Walker JM, Matoba N, O'Keefe BR, Palmer KE: Investigation of Griffithsin's Interactions with Human Cells Confirms Its Outstanding Safety and Efficacy Profile as a Microbicide Candidate. PLoS One 2011, 6:e22635.
• [26]Martin G, Burke B, Thaï R, Dey AK, Combes O, Ramos OH, Heyd B, Geonnotti AR, Montefiori DC, Kan E, Lian Y, Sun Y, Abache T, Ulmer JB, Madaoui H, Guérois R, Barnett SW, Srivastava IK, Kessler P, Martin L: Stabilization of HIV-1 envelope in the CD4-bound conformation through specific cross-linking of a CD4 mimetic. J Biol Chem 2011, 286:21706-21716. Erratum in: J Biol Chem 2011, 286:29442